CN115215808B - 用于治疗癌症的组合物和方法 - Google Patents
用于治疗癌症的组合物和方法 Download PDFInfo
- Publication number
- CN115215808B CN115215808B CN202210268803.XA CN202210268803A CN115215808B CN 115215808 B CN115215808 B CN 115215808B CN 202210268803 A CN202210268803 A CN 202210268803A CN 115215808 B CN115215808 B CN 115215808B
- Authority
- CN
- China
- Prior art keywords
- compound
- depicts
- nmr
- cancer
- erlotinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819322P | 2019-03-15 | 2019-03-15 | |
| US62/819,322 | 2019-03-15 | ||
| US201962904241P | 2019-09-23 | 2019-09-23 | |
| US62/904,241 | 2019-09-23 | ||
| CN202080034742.XA CN113811528A (zh) | 2019-03-15 | 2020-03-13 | 用于治疗癌症的组合物和方法 |
| PCT/US2020/022743 WO2020190765A2 (en) | 2019-03-15 | 2020-03-13 | Compositions and methods for treating cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080034742.XA Division CN113811528A (zh) | 2019-03-15 | 2020-03-13 | 用于治疗癌症的组合物和方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115215808A CN115215808A (zh) | 2022-10-21 |
| CN115215808B true CN115215808B (zh) | 2025-04-18 |
Family
ID=72521289
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210268803.XA Active CN115215808B (zh) | 2019-03-15 | 2020-03-13 | 用于治疗癌症的组合物和方法 |
| CN202080034742.XA Pending CN113811528A (zh) | 2019-03-15 | 2020-03-13 | 用于治疗癌症的组合物和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080034742.XA Pending CN113811528A (zh) | 2019-03-15 | 2020-03-13 | 用于治疗癌症的组合物和方法 |
Country Status (17)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240017986A (ko) * | 2017-09-26 | 2024-02-08 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 조성물 및 방법 |
| KR102809395B1 (ko) | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| WO2022061201A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022155311A1 (en) * | 2021-01-14 | 2022-07-21 | The Regents Of The University Of California | Methods and systems for analysis of drug target engagement and treatment of cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| US20240165132A1 (en) * | 2021-05-12 | 2024-05-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN113307799B (zh) * | 2021-05-21 | 2022-07-19 | 大连医科大学 | 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用 |
| CA3233057A1 (en) * | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
| US20260108524A1 (en) * | 2022-10-14 | 2026-04-23 | The Regents Of The University Of California | Egfr inhibitors for treating lung cancer |
| WO2024102177A1 (en) * | 2022-11-08 | 2024-05-16 | The Regents Of The University Of California | Combination therapies for the treatment of brain cancer |
| AU2024388187A1 (en) * | 2023-11-27 | 2026-06-18 | Katmai Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법 |
| CN1854130B (zh) | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| WO2008046242A1 (fr) | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
| EP2484678B1 (en) | 2009-09-28 | 2015-01-21 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors |
| ITPD20110091A1 (it) | 2011-03-24 | 2012-09-25 | Univ Padova | Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico. |
| CA3081443A1 (en) * | 2014-12-15 | 2016-06-23 | The Regents Of The University Of Michigan | Small molecule inhibitors of egfr and pi3k |
| WO2016123706A1 (en) * | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
| CN105017163A (zh) | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| US10473255B2 (en) | 2015-12-29 | 2019-11-12 | Ge-Hitachi Nuclear Energy Americas Llc | Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device |
| CA3008312A1 (en) | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
| CN106432202B (zh) | 2016-09-22 | 2019-04-02 | 郑州大学第一附属医院 | 喹唑啉类衍生物及其应用 |
| KR20240017986A (ko) * | 2017-09-26 | 2024-02-08 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 조성물 및 방법 |
| KR102809395B1 (ko) * | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061201A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| CA3233057A1 (en) * | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
-
2020
- 2020-03-13 KR KR1020217032873A patent/KR102809395B1/ko active Active
- 2020-03-13 WO PCT/US2020/022743 patent/WO2020190765A2/en not_active Ceased
- 2020-03-13 CR CR20210498A patent/CR20210498A/es unknown
- 2020-03-13 CA CA3133688A patent/CA3133688A1/en active Pending
- 2020-03-13 MX MX2021011272A patent/MX2021011272A/es unknown
- 2020-03-13 EP EP20773177.9A patent/EP3938354A4/en active Pending
- 2020-03-13 SG SG11202109662Y patent/SG11202109662YA/en unknown
- 2020-03-13 PH PH1/2021/552208A patent/PH12021552208A1/en unknown
- 2020-03-13 BR BR112021018295A patent/BR112021018295A2/pt unknown
- 2020-03-13 CN CN202210268803.XA patent/CN115215808B/zh active Active
- 2020-03-13 CN CN202080034742.XA patent/CN113811528A/zh active Pending
- 2020-03-13 AU AU2020241703A patent/AU2020241703B2/en active Active
- 2020-03-13 JP JP2021555445A patent/JP7474269B2/ja active Active
-
2021
- 2021-09-13 IL IL286350A patent/IL286350A/en unknown
- 2021-09-14 US US17/475,144 patent/US11377451B2/en active Active
- 2021-09-15 SA SA521430328A patent/SA521430328B1/ar unknown
- 2021-09-15 CL CL2021002409A patent/CL2021002409A1/es unknown
- 2021-10-11 CO CONC2021/0013496A patent/CO2021013496A2/es unknown
-
2022
- 2022-06-29 US US17/853,573 patent/US20230115366A1/en not_active Abandoned
-
2024
- 2024-04-12 JP JP2024064400A patent/JP7789832B2/ja active Active
- 2024-06-12 US US18/741,322 patent/US20250145634A1/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| "7-Substituted-[1, 4]dioxano[2, 3-g]quinazolines as Inhibitors of Epidermal Growth Factor Receptor Kinase";Jae Yeol Lee等;《Arch. Pharm. Pharm. Med. Chem.,》;第35卷(第10期);第487–494页 * |
| "Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors";Tsang, Jonathan E.等;《ACS Medicinal Chemistry Letters》;第11卷(第10期);第1799-1809页 * |
| Jae Du Ha等."Design and Synthesis of Novel Epidermal Growth Factor Receptor Kinase Inhibitors".《Bull. Korean Chem. Soc.,》.2005,第26卷(第6期),第959-965页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230115366A1 (en) | 2023-04-13 |
| CN115215808A (zh) | 2022-10-21 |
| KR20210151820A (ko) | 2021-12-14 |
| EP3938354A4 (en) | 2022-12-28 |
| IL286350A (en) | 2021-10-31 |
| BR112021018295A2 (pt) | 2021-11-23 |
| JP7789832B2 (ja) | 2025-12-22 |
| PH12021552208A1 (en) | 2022-05-30 |
| CR20210498A (es) | 2022-01-11 |
| CL2021002409A1 (es) | 2022-06-17 |
| US11377451B2 (en) | 2022-07-05 |
| AU2020241703B2 (en) | 2026-02-05 |
| JP7474269B2 (ja) | 2024-04-24 |
| JP2024102094A (ja) | 2024-07-30 |
| MX2021011272A (es) | 2021-10-01 |
| US20250145634A1 (en) | 2025-05-08 |
| WO2020190765A3 (en) | 2020-11-26 |
| EP3938354A2 (en) | 2022-01-19 |
| SA521430328B1 (ar) | 2024-03-28 |
| WO2020190765A2 (en) | 2020-09-24 |
| AU2020241703A1 (en) | 2021-10-14 |
| CN113811528A (zh) | 2021-12-17 |
| CO2021013496A2 (es) | 2022-01-17 |
| KR102809395B1 (ko) | 2025-05-16 |
| CA3133688A1 (en) | 2020-09-24 |
| SG11202109662YA (en) | 2021-10-28 |
| US20220064177A1 (en) | 2022-03-03 |
| JP2022526266A (ja) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7474269B2 (ja) | がんを治療するための組成物及び方法 | |
| AU2023282187B2 (en) | Compositions and methods for treating cancer | |
| JP6193268B2 (ja) | Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 | |
| US20120077811A1 (en) | Prodrug forms of kinase inhibitors and their use in therapy | |
| US20240058340A1 (en) | Compositions and methods for treating cancer | |
| US20230364091A1 (en) | Compositions and methods for treating cancer | |
| HK40083017A (en) | Compositions and methods for treating cancer | |
| HK40062377A (en) | Compositions and methods for treating cancer | |
| WO2013144632A1 (en) | Treatment of proliferative diseases with pyrimidodiazepinones | |
| EA044668B1 (ru) | Композиции и способы для лечения рака | |
| WO2014106763A1 (en) | Pyridopyrazines as anticancer agents | |
| HK40037064A (en) | Compositions and methods for treating cancer | |
| US20180303797A1 (en) | Chalcone Compounds | |
| Goerguen et al. | MLN-8237 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40083017 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |